Ovid Therapeutics (OVID) Net Cash Flow Growth (5y) (2021 - 2026)
Ovid Therapeutics (OVID) Net Cash Flow Growth (5y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,861.65 Bn | 66,861.36 Bn | - |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.90 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.46 Bn | 37.46 Bn | - |
| 10 | Ovid Therapeutics | 120.41 Mn | -35.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -12.83% |
| Dec 31, 2025 | 13.32% |
| Sep 30, 2025 | -16.76% |
| Jun 30, 2025 | -12.27% |
| Mar 31, 2025 | 18.72% |
| Dec 31, 2024 | 23.12% |
| Sep 30, 2024 | -9.20% |
| Jun 30, 2024 | 31.68% |
| Mar 31, 2024 | -27.10% |
| Dec 31, 2023 | -47.94% |
| Sep 30, 2023 | -30.46% |
| Jun 30, 2023 | 26.86% |
| Mar 31, 2023 | 18.27% |
| Dec 31, 2022 | -8.47% |
| Sep 30, 2022 | -7.64% |
| Jun 30, 2022 | -28.59% |
| Mar 31, 2022 | -22.33% |
| Dec 31, 2021 | -15.75% |
| Sep 30, 2021 | -17.18% |
| Jun 30, 2021 | -42.01% |